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Chronic inflammation, regardless of infectious agents, plays important roles in the 
development of various cancers particularly in digestive organs, including Helicobacter 
pylori (H. pylori)-associated gastric cancer, hepatitis C virus (HCV)-positive 
hepatocellular carcinoma, and colitis-associated colon cancers. Cancer development is 
characterized by stepwise accumulation of genetic and epigenetic alterations of various 
proto-oncogenes and tumor suppressor genes. During chronic inflammation, infectious 
agents such as H. pylori and HCV as well as intrinsic mediators of inflammatory 
responses, including proinflammatory cytokines and reactive oxygen and nitrogen 
species, can induce genetic and epigenetic changes, including point mutations, deletions, 
duplications, recombinations, and methylation of various tumor-related genes through 
various mechanisms. Furthermore, inflammation also modulates the expressions of 
microRNAs that influence the production of several tumor-related mRNAs or proteins. 
These molecular events induced by chronic inflammation work in concert to alter 
important pathways involved in normal cellular function, and hence accelerate 
inflammation-associated cancer development. Among these, recent studies highlighted 
an important role of activation-induced cytidine deaminase, a nucleotide-editing enzyme 
essential for somatic hypermutation and class-switch recombination of the 
immunoglobulin gene, as a genomic modulator in inflammation-associated cancer 
development.   
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Abbreviations used in this paper: 5-mC, 5-methyl cytosine; 8-OHdG, 
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severe combined immunodeficiency; STAT3, signal transducer and activator of 
transcription 3; SIRT1, sirtuin 1; STAT6, signal transducer and activator of transcription 
6; SVR, sustained virological response; T, thymine; Th2, T helper 2 cell; THDB, 
thrombomodulin; TET1, ten-eleven translocation 1; TLRs, toll-like receptors; TNF-α, 
tumor necrosis factor-α; U, uracil; UNG, uracil DNA glycosylase; WEE1, mitosis 








- 3 - 
Introduction 
 
Nearly 150 years ago, Rudolf Virchow noted that inflammatory cells are present in 
tumor tissues and that tumors develop at sites of chronic inflammation; he suggested 
that chronic inflammation plays important roles in cancer development. Since then, 
many clinical and epidemiological studies have confirmed a strong association between 
inflammation and cancer
1, 2
. For instance, epidemiological studies have shown that 
approximately 10-15% of cancers were related to chronic infections with viruses, 
bacteria or parasites
3-7
, and moreover, that up to 25% of all cancers were associated with 
chronic inflammation irrespective of the presence or absence of infection
5-7
. 
In inflammation-associated cancer development, in addition to infectious agents 
such as Helicobacter pylori (H. pylori) and hepatitis C virus (HCV), many intrinsic 
mediators of inflammation including proinflammatory cytokines, eicosanoids, growth 
factors, and reactive oxygen species (ROS) and reactive nitrogen species (RNS) exert 
important effects in cancer development through various mechanisms. These include 
enhancement of cell growth and mobility, induction of angiogenesis, and inhibition of 
apoptosis. However, a hallmark of cancer development is the stepwise accumulation of 
various genetic and epigenetic alterations of the genome. Indeed, recent genome-wide 
analysis of human cancer tissues revealed that a single cancer cell generally possesses 
approximately 100 mutations in coding regions, 10-20 of which are known as “driver 
genes” that contribute to cancer development8-10, and moreover, that there are many 
somatic gene rearrangements, including duplications, deletions and inversions in human 
cancer genomes
11, 12
. In addition to genetic alterations, recent studies have also shown 
that chronic inflammation enhances epigenetic changes as represented by DNA 
methylation
13
. It is estimated that several hundreds to thousands of genes are methylated 
in a cancer cell
14
, and that aberrant DNA methylation is present even in 
normal-appearing tissues, being involved in field cancerization
13, 15, 16
.  
Digestive organs are inhabited by many microorganisms and are infiltrated by many 
immune cells in physiological and pathological conditions, and thus they are more or 
less accompanied by certain levels of inflammation. Here, we review mechanisms of 
how inflammation is involved in cancer development in digestive organs, particularly 
focusing on the role of chronic inflammation in inducing genetic and epigenetic 
changes. 
 
Cancers in Digestive Organs Associated with Inflammation 
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Many cancers arise in digestive organs. Indeed, gastric cancer remains the third 
leading cause of cancer death in men and the fifth in women, and colorectal cancer is 
the third most commonly diagnosed cancer in men and the second most in women 
world-wide
17
. In addition, hepatocellular carcinoma (HCC) is one of the most frequent 
malignancies and its incidence is increasing not only in an endemic area for the hepatitis 
virus but also in the United States and other western countries
18
. Digestive organs cover 
a large part of the body surface in contact with the outer environment. Accordingly, they 
are not only inhabited by many microorganisms but also exposed to ingested food or 
chemical agents, and therefore infiltrated by many immune cells in pathological as well 
as normal conditions, supporting the perpetuation of chronic inflammation. Therefore, it 
is reasonable that many cancers in digestive organs are associated with inflammation. 
The best examples of inflammation-associated cancer in humans are gastric cancer 
and HCC. Since the discovery of H. pylori by Warren and Marshall in 1982
19
, it has 
been well established that H. pylori-positive patients with chronic gastritis have a 
significantly higher risk for gastric cancer than H. pylori-negative subjects
20
, and 
moreover, careful investigations have shown more than 95% positivity for H. pylori 
infection in gastric cancer patients
21
. On the other hand, hepatitis B virus (HBV) and 
HCV infections account for approximately 60% and 33% of the total HCC cases in 
developing countries and 23% and 20% in developed countries, respectively
6, 22
, and the 
majority of HCCs develop in patients who have chronic hepatitis or liver cirrhosis. 
Other inflammation-associated cancers in digestive organs are colitic cancers developed 
in patients with inflammatory bowel disease (IBD) or celiac disease 
23-25
, primary 
sclerosing cholangitis (PSC)-associated cholangiocarcinoma
26
, primary biliary 
cirrhosis-associated HCC
27, and Barrett’s cancer developed in patients with reflux 
esophagitis
28
. In addition, the incidence of pancreatic cancer in patients with chronic 
pancreatitis is reported to be 4-8 times higher than in the general population
29
, and more 
strikingly, the incidence of pancreatic cancer in patients with hereditary pancreatitis is 
53 times higher than in the normal population
30
, indicating that chronic pancreatitis is a 
risk for pancreatic cancer.  
In addition to cancers, inflammation is also a risk for developing various 
lymphomas in digestive organs. These include H. pylori-induced mucosa-associated 





and lymphoma related to celiac disease
34
.   
 
Mechanisms for Inflammation-Associated Cancer Development 
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The inflammatory response is coordinated by a large range of mediators, which are 
released from immune cells, mesenchymal cells and epithelial cells; these mediators 
exert various functions in maintaining or resolving inflammation, and at the same time 
are involved in cancer development. Among the mediators, cytokines play central roles 
in diversifying the inflammatory process, and interleukin (IL)-1β, tumor necrosis 
factor (TNF)-α , and IL-6 are known to be the major cytokines important for 
inflammation and cancer development
35-37
. 
IL1-β  and TNF-α  act directly on epithelial cells to induce activation of 
transcription factor nuclear factor-κB (NF-κB), a key transcription factor mediating  
inflammation and cancer development
36, 37
. NF-κB activation not only promotes 
growth or suppresses apoptosis of epithelial cells but also stimulates the production of 
growth factors and cytokines such as epidermal growth factor (EGF) and IL-6, enhances 
cyclooxygenase (COX)2 induction, and increases ROS production
38
. The induced 
COX-2 subsequently has many functions, including enhancement of cell growth and 
angiogenesis
39
. ROS modifies protein function
40
. IL-6 activates signal transducer and 
activator of transcription 3 (STAT3) and thereby enhances cell growth, and stimulates 
growth factor production, including the Reg protein
41
. Interestingly, TNF-α and IL-6 
often create a positive-feedback loop during cancer development
42
.  
At the same time, these cytokines also activate mitogen-activated protein kinase 
(MAPK) cascades. For instance, TNF-α and IL-6 have been shown to activate the 
extracellular signal-regulated kinase (ERK)/MAPK cascade, an important signaling 
pathway involved in many processes in carcinogenesis including cell proliferation, 
migration, and angiogenesis
43, 44
. Similarly, IL1-β, TNF-α, and IL-6 all activate c-Jun 
N-terminal kinase (JNK). Although JNKs are primarily attributed to proapoptotic cell 
death or tumor suppression in response to inflammation or various stressors
45
, JNK 
activation, particularly JNK1, by proinflammatory cytokines has been reported to 
contribute to inflammation-associated cancer development through cell death-induced 
“compensatory proliferation”45-48. In this regard, an interesting thing to note is that H. 




Thus, these mediators of inflammation form a complex of regulatory networks, and 
appear to work in concert to enhance cancer development. However, for normal cells to 
be eventually transformed and become cancer cells with clonal expansion, inflammation 
has to damage cellular DNA, either genetically or epigenetically, leading to permanent 
alteration within the genome. 
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Inflammation and Genetic Modulation 
 
Cancer is a genetic disease resulting from stepwise accumulation of genetic and 
epigenetic alterations that drives the progressive transformation of normal cells into 
malignant derivatives
51
. Inactivation of tumor-suppressor genes and/or activation of 
oncogenes caused by somatic mutations, DNA copy number changes, or chromosomal 
aberrations are widely detectable in human cancer cells.  Among them, the tumor 
suppressor TP53 gene is one of the most frequent targets for genetic alterations in many 
human cancers
52
.  An important point to note is that TP53 mutations are frequently 
present also in non-cancerous tissues with chronic inflammation before cancer 
development. Indeed, multiple genetic changes in the TP53 gene have been detected in 
various inflammatory tissues such as IBD
53, 54, Barrett’s esophagus55 and 
HCV-associated chronic hepatitis
56
. For example, by analyzing the individual crypt 
mutation burden across plaques of the dysplasia, it was shown that mutations in TP53 
genes could be identified in the majority of inflamed crypts of patients with ulcerative 
colitis (UC)
57
. Moreover, TP53 mutations are detectable at the frequencies of 4-15 
nucleotides out of 10
4
 nucleotides in the hepatocytes of the patients with chronic HCV 
infecction
56
. Normal mutation rates cannot account for such abundant genetic changes 
that accumulate in inflamed epithelial cells, suggesting that certain molecular 
mechanisms underlie such a large number of genetic alterations. Therefore, to 
understand the mechanisms of inflammation-associated tumorigenesis, several possible 
intrinsic mutagens responsible for genetic aberrations in the inflammatory condition 
have been proposed. Among them, free radicals and intrinsic DNA mutator enzymes 
appear to be important candidates in the setting of chronic inflammation (Figure 1).  
Free radicals refer to any molecular species with one or more unpaired electron(s), 
including ROS and RNS
38
. Interestingly, increases in TP53 gene mutations at codons 
247 and 248 are paralleled by an enhanced expression of nitric oxide synthase (iNOS) 
in the inflamed lesions of the colonic tissues of patients with ulcerative colitis
54
. HCV 
infection also induces iNOS mRNA expression, thereby enhancing nitric oxide (NO) 
production, which in turn results in DNA breaks and enhanced mutation frequencies
58
. 
Moreover, an increased level of NO accelerated spontaneous tumor development, 




In the inflammatory condition, cellular ROS levels are substantially elevated, and 
nucleic acids exposed to ROS generate various modified bases such as oxidatively 
altered purines and pyrimidines
60
. These modified nucleic acids could induce the 
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putative DNA damage, including single- or double-stranded DNA breaks, DNA 
intrastrand adducts, and DNA protein crosslinks
61
. In addition, ROS alters the mismatch 
repair function and allows mutations to accumulate in microsatellite sequences
62
. It has 
been well recognized that oncogene activation is capable of inducing genomic 
instability in precancerous lesions as well as cancer cells
63
. In this regard, ROS is also a 
a putative mediators that links excessive activity of oncogene products and DNA 
damage.  For example, oncogene c-MYC overexpression results in DNA damage prior 
to the S phase in association with the ROS induction in normal human fibroblasts
64
. 
These findings suggested that the cumulative situation of ROS production, a condition 
of so-called oxidative stress, is involved in both the initiation and progression of 
inflammation-associated cancers through the induction of genetic instability.  
Importantly, the typical mutation pattern induced by oxidative stress cannot account 
for a mutation signature observed in many human cancer tissues, particularly in 
inflammation-associated cancers.  Among the oxidized nucleosides, one of the 
common products of free radical attack on DNA is 8-hydroxydeoxyguanine (8-OHdG), 
which is considered to be a biomarker of oxidative stress
65
. The typical pattern of 
nucleotide alterations induced by 8-OHdG is guanine (G)/cytosine (C) to thymine 
(T)/adenine (A) transversions, which have been observed in the RAS oncogene and 
TP53 tumor suppressor gene in lung and liver cancers
66, 67
.  However, recent genome 
wide analyses clearly demonstrated that G/C to T/A transversions account for a minor 
proportion of the total mutations identified in human cancer cells, and instead C/G to 
T/A transitions are the most prevalent mutation pattern in various cancer tissues, 
including inflammation-associated cancers
68
. Thus, it appears reasonable to assume that 
there is an alternative mechanism that accounts for the most frequent mutational pattern, 
C/G to T/A transitions, detected in many human cancer tissues. 
Recently, several human enzymes that are capable of inducing nucleotide alterations 
have been identified, providing a new avenue for understanding mutagenesis 
mechanisms 
69
. Among them, activation-induced cytidine deaminase (AID) is a well 
defined molecule involved in DNA mutations in the human genome. Through its 
enzymatic activity, AID can deaminate C on target DNA to produce a uracil (U), and 
therefore turns a DNA C:G pair into a U:G mismatch. When DNA replication starts 
before recognition by the repair system, a U:G mismatch gives rise to C/G to T/A 
transition. Alternatively, recognition of a U:G mismatch by uracil-DNA-glycosylase 
(UNG) or mutS homolog 2 (MSH2)/mutS homolog 6 (MSH6) heterodimer induces 
mutations in the U:G mismatch or at the nearby A:T site (Figure 2). As a result, AID can 
induce any type of mutations
70
. Under physiological conditions, AID contributes to 
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generating antibody gene diversification in activated B lymphocytes by inducing 
somatic hypermutation and class switch recombination of immunoglobulin gene
71
.  In 
sharp contrast to the favorable function of AID in the immune system, the role of AID in 
tumorigenesis through induction of genetic instability was first suggested in 
hematopoietic malignancies. A number of studies have demonstrated that increased AID 
expression in various neoplasms of the B lymphocytic lineage was associated with 
unfavorable mutations and chromosomal translocations
72, 73
. For instance, AID has been 
shown to be responsible for the chromosomal breaks in c-MYC leading to a 
c-MYC/immunoglobulin H (IGH) translocation in B cell lymphoma
74
. Moreover, AID 
induces breakpoint cluster region (BCR)-Abelson murine leukemia viral oncogene 
homolog 1 (ABL1) mutations leading to Imatinib resistance in chronic myeloid leukemia 
cells
75
. Since the target of AID-mediated genotoxic effects was not restricted to 
immunoglobulin genes and a variety of other genes also received the AID-mediated 
mutations in B cells
70
, it was not surprising that aberrant upregulation of AID induced 
genetic alterations in various tumor-related genes, leading to the transformation of 
hematopoietic cells.   
As described, activation of NF-κB is induced in response to various inflammatory 
stimulations, and is deeply involved in multiple processes of cancer initiation and 
progression 
36
. Interestingly, NF-κB is a major transcription factor for AID in B cells 
that is activated through cluster of differentiation 40-TNF receptor superfamily member 
5 (CD40) ligation by T cells
76
, suggesting that AID might link NF-κB activation and 
genetic instability in non-lymphoid cells in the setting of inflammation. In agreement 
with this hypothesis, AID expression is induced in response to proinflammatory 
cytokine stimulation via the NF-κB-dependent pathway in various epithelial cells 
(Figure 3).  In hepatocytes, AID expression is induced by TNF-α through the I-κB 
kinase (IKK)-dependent NF-κB signaling pathway77. Consistent with a previous 
finding that the HCV core protein triggers the activation of NF-κB in hepatocytes78, 
the HCV core protein itself also up-regulates endogenous AID in cultured hepatocytes
77
. 
NF-κB-mediated induction of AID expression is not limited to hepatocytes. In human 
gastric epithelial cells, AID expression is induced by TNF-α stimulation via activation 
of NF-κB, but not detected in non-stimulated cells79. More interestingly, aberrant AID 
expression is induced by the infection of a pathogenic H. pylori strain, the 
cytotoxin-associated gene pathogenicity island (CagPAI)-positive strain that is capable 
of introducing bacterial virulence factors into the host cells through a type-IV secretion 
system and activating NF-κB, indicating that both bacterial factors introduced into 
epithelial cells and the inflammatory mediators such as TNF-α and IL-1β induced by 
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H. pylori infection cooperatively promote aberrant AID expression in H. pylori-infected 
gastric mucosal cells.  Similar to hepatocytes and gastric mucosal cells, TNF-α 
stimulation resulted in upregulation of endogenous AID in human colonic cells via the 
IKK-dependent NF-κB signaling pathway80. In addition, IL-4 and IL-13, which are 
involved in Th2 type immune response in IBD, induced aberrant AID expression in a 
signal transducer and activator of transcription 6 (STAT6)-dependent manner in human 
colonic epithelial cells
80
. Of note, IL-4 is known to induce AID also in B cells
71
. 
Consistent with the in vitro analyses, aberrant AID expression is widely detectable 
in not only various inflammation-associated cancer tissues but also in a variety of 
inflamed epithelial tissues where tumorigenic risk is high, including chronic hepatitis 
and cirrhosis caused by HCV infection
56







, and the columnar cell-lined Barrett’s esophagus82.  
The impact of AID expression in non-lymphoid epithelial cells was clarified using 
both in vivo and in vitro systems with aberrant AID expression. Constitutive and 
ubiquitous AID expression in transgenic mice induced lymphoma development via the 
accumulation of somatic mutations in various non-immunoglobulin genes, including the 
proto-oncogene c-Myc
83
. More importantly, further phenotypic analyses revealed that 
AID transgenic mice also develop neoplasia in epithelial tissues, including lung, liver 
and stomach accompanied by the emergence of Trp53 mutations, indicating that 
aberrant AID expression in epithelial cells can induce genetic instability leading to 
cancer development
83, 84
. It is widely recognized that the frequently mutated 
tumor-related genes differ among different cancers. For instance, nucleotide alterations 
in the K-RAS are detectable in almost all human pancreatic cancers
85
, while it is 
relatively low in other human tumors.  Similarly, the c-MYC is a frequent target for 
genetic alterations in human lung cancers, while its nucleotide alterations are rare in 
hepatocellular carcinoma
86
. However, the mechanisms underlying the accumulation of 
organ-specific genomic changes in oncogenic pathways are not well known. 
Interestingly, organ-specific changes in mutational profiles were observed in the 
epithelial tissues of the AID transgenic mice. Indeed, the c-Myc gene was frequently 
mutated in non-cancerous tissue of the lung, while K-ras gene mutations were 
frequently detectable in gastric cancer developed in AID transgenic mice
84
. Thus, the 
organ-specific differences in the mutational profiles in AID transgenic mice suggest the 
possibility that the target preference of AID-induced mutagenesis in different tissues 
might contribute to the diversity of tissue-specific oncogenic pathways in various 
epithelial organs.  
In vitro analyses using human cultured cells with constitutive AID expression 
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revealed that TP53 mutations were frequently induced by AID genotoxic activity in 
hepatocytes, and gastric, colonic, and bile duct epithelial cells
77, 79-81
.  Similar to the 
TP53 gene, the cyclin-dependent kinase inhibitor (CDKN)-2B-CDKN2A locus was 
identified as a target for AID-mediated genotoxic activity. The CDKN2B-CDKN2A 







regulate the activities of the retinoblastoma protein (RB) and the TP53 transcription 
factor. Aberrant AID expression preferentially induces somatic mutations at the 
CDKN2B-CDKN2A locus in gastric epithelial cells and biliary cells
81, 87
. Moreover, 
comparative genomic hybridization analysis clearly demonstrated that constitutive AID 
activation in cultured gastric epithelial cells caused submicroscopic deletions as 
represented by copy number losses of various chromosomal loci, especially at the 
CDKN2B-CDKN2A locus at 9p21. Copy number reduction of Cdkn2b-Cdkn2a was also 
seen in the gastric mucosa of AID transgenic mice
87
. In agreement with the preferential 
deletions at the CDKN2B-CDKN2A locus in gastric epithelial cells by AID introduction, 
AID expression was required for inducing DNA single-strand breaks in the CDKN2B 
gene in leukemia cells
88
, and furthermore, the deletion of the CDKN2B-CDKN2A locus 
is frequently detectable in AID-expressing lymphoid blast crisis leukemia cells
75
. These 
findings suggest that AID can induce both mutations and deletions at the same gene 
locus, and moreover, that the representative tumor-suppressor genes, TP53 and 
CDKN2B-CDKN2A may be common targets for AID-mediated genotoxic effects in 
various human tissues in the setting of inflammation.  
Finally, a recent finding that a deficiency of endogenous AID reduced the incidence 
of both accumulation of somatic mutations in the Trp53 gene and the development of 
colitis-associated colorectal cancers further supports the critical role of AID in 





Inflammation and Epigenetic Modulation 
 
Epigenetic modifications are DNA-associated modifications that are inherited upon 
somatic cell replication, which include DNA methylation and histone modifications
90
. 
Coordinated changes of epigenetic modifications control development and tissue 
differentiation, and erasure of epigenetic modifications is involved in reprogramming. 
In somatic cells, DNA methylation is present in repetitive elements, CpG-sparse regions, 
and in a very limited number of CpG islands
91, 92
. DNA methylation of a CpG island in a 
promoter region causes silencing of its downstream gene, whether it is a protein-coding 
- 11 - 
gene or a miRNA gene, by forming nucleosomes and thus possibly blocking access of 
RNA polymerase II to the promoter
93, 94
. In contrast, DNA methylation of a gene body is 
often associated with increased gene expression
91, 95
.  
Histone modifications denote chemical modifications, such as acetylation, 
methylation, and ubiquitination of lysine and arginine residues of histones, mainly H3 
and H4 but also H2A and H2B
93
. Specific histone modifications, such as acetylation of 
histones H3 and H4 (H3Ac and H4Ac) and trimethylation of lysine 4 of histone H3 
(H3K4 me3) are associated with active gene transcription. In contrast, di- and 
trimethylation of H3 lysine 9 (H3K9 me2 and H3K9 me3) and trimethylation of H3 
lysine 27 (H3K27 me3) are associated with gene repression. H3K9 me2 represses gene 
transcription in concert with DNA methylation, while H3K27 me3 works independently 
of DNA methylation
96
. Trimethylation of H3 lysine 36 (H3K36 me3) is considered to 
mark exonic regions of active genes. However, the mechanisms of how histone 
modifications are inherited upon somatic cell replication remains unclear
97
. 
In cancer cells, the presence of regional hypermethylation and global 
hypomethylation has been described
98, 99
. Regional hypermethylation refers to aberrant 
DNA methylation of promoter CpG islands physiologically kept unmethylated
95, 100
. If 
aberrant methylation is induced in a promoter CpG island, it consistently induces 
silencing of its downstream gene
90
. Many tumor-suppressor genes that have promoter 
CpG islands, such as CDKN2A, mutL homolog 1 (MLH1), cadherin-1 (CDH1), and 
RAS-association domain family 1, isoform A (RASSF1A), can be permanently 
inactivated by aberrant DNA methylation as drivers, that have significant roles in cancer 
development. At the same time, most of the aberrant DNA methylation of promoter 
CpG islands are considered to be passengers, that play no role in carcinogenesis
14
. 
Several hundreds to thousands of promoter CpG islands are aberrantly methylated in a 
cancer, and the number is too large for all of them to be drivers.  Moreover, most of the 
genes methylated in cancers are not expressed in normal tissues
101, 102
, and such genes 
are considered to be not involved in carcinogenesis. Global hypomethylation was shown 
to be causally involved in carcinogenesis by inducing genomic instability
103
. In addition, 
induction of H3K27 me3 is considered to be an alternative mechanism to induce gene 
silencing
96
, and aberrant H3K27 me3 was observed in promoter regions consisting of 
200-600 genes
96, 104
. Again, the number is very large, and most are expected to be 
passengers.  
As inducers of aberrant DNA methylation, aging was first indicated
105
, and chronic 
inflammation was then suggested by the presence of aberrant DNA methylation of 
specific tumor-suppressor genes in non-cancerous colonic mucosae of patients with 
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IBD
106, 107
. Aberrant DNA methylation was present more frequently in liver tissues of 
patients with HCC than in those with metastatic liver tumors
108
. By measuring 
methylation levels of passenger genes in gastric mucosae of H. pylori-infected 
individuals, a very close association between H. pylori infection and high methylation 
levels in gastric mucosa was demonstrated
15
. Aberrant DNA methylation is particularly 
prominent in chronic inflammation-associated cancers, such as gastric cancer, HCCs, 
colitic cancer, cholangiocarcinoma, Barrett’s cancer, and pancreatic cancer13. These 
findings strongly indicated that the major inducer of aberrant DNA methylation is 
chronic inflammation.  
Levels of aberrant DNA methylation accumulated in normal-appearing tissues 
correlate with the risk of gastric, colon, breast, and renal cancers
15, 109-112
. Such 
accumulation mainly involves passenger and driver genes to some extent, and is 
considered to form an epigenetic field for cancerization (epigenetic field defect) (Figure 
4)
113
. Chronic inflammation-associated cancers are known to show multiple events, 
which can be explained by the presence of a field defect in normal-appearing tissues. 
Along with the accumulation of genetic alterations, an epigenetic field defect is deeply 
involved in the development of inflammation-associated cancers. The degree of 
epigenetic field defect can be easily measured using methylation levels of marker 
genes
114
, which are passenger genes in most cases and show relatively high methylation 
levels in predisposed tissues
113
.  
Mechanistic studies, including cause and effect of accumulated aberrant DNA 
methylation and chronic inflammation, were conducted using animal models. When H. 
pylori-induced inflammation was suppressed by cyclosporine A in Mongolian gerbils, 
induction of aberrant DNA methylation was markedly suppressed, while the number of 
H. pylori in gastric mucosae was unaffected
16
. This indicated that inflammation, not H. 
pylori itself, is critical for induction of aberrant DNA methylation. Expression analysis 
of inflammation-related genes showed that expression levels of Il1b, Nos, Tnf, and 
chemokine (C-X-C motif) ligand 2 (Cxcl2) correlated with methylation levels in gastric 
mucosae. H. pylori-induced inflammation was capable of inducing aberrant DNA 
methylation, but not repeated induction of acute inflammation by ethanol or a high 
sodium concentration
115
. Il1β, Nos2 and Tnf were specifically upregulated by the H. 
pylori-induced inflammation. Notably, in humans, a polymorphism of the IL1B 
promoter was associated with not only gastric cancer susceptibility
35
, but also the 
presence of the CpG island methylation phenotype in gastric cancers
116
.  
Another animal model for methylation induction by chronic inflammation is mouse 
colitis induced by administration of dextran sulfate sodium (DSS)
117
. Aberrant DNA 
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methylation of multiple genes occurred in DSS-induced colitis mucosae before 
induction of colon tumors, showing an epigenetic field
118
. The induction of aberrant 
DNA methylation was unaffected even in severe combined immunodeficiency (SCID) 
mice that lacked T and B cells, suggesting that infiltrated macrophages might be critical 
for methylation induction. Gene expression analysis in colonic mucosae in wild-type 
and SCID mice showed that expression levels of Il1b, Nos, and Ifng were associated 
with methylation induction in colonic mucosae. Taken together with the finding in the H. 
pylori-infected gerbils, infiltration of macrophages and resulting secretion of Il-1β and 
Tnf-α as well as production of active oxygen species are believed to be involved in 
induction of aberrant DNA methylation in epithelial cells (Figure 1).  
Several in vitro studies have been conducted to examine inflammatory signals that 
lead to methylation induction in target cells. Treatment of insulinoma or blood cells with 
IL-1β or a NO donor induced methylation of endogenous genes by increasing activity 
of DNA methyltransferase(s) (DNMTs)
119
. IL-6 induces DNMT1 transcription by 
increasing its promoter activity and suppressing miR-148a and miR-152, both of which 
target DNMT1
120,121. 
Although some studies suggested that DNA methylation is induced 
by IL-1β or IL-6, the changes were marginal possibly because identification of 
appropriate target CpG islands was difficult and the levels of increase were too small to 
be detected by ordinary methods. Prostaglandin E2 treatment of cancer cell lines 
increased DNMT1 and DNMT3B expression, and induced DNA methylation of specific 
genes, which was also observed in vivo
122
.   
In contrast to in vitro studies, mRNA expression levels of Dnmt1, Dnmt3A, and 
Dnmt3B were not increased in vivo, such as colonic mucosae with DSS-induced colitis 
16
, and human gastric tissues with H. pylori infection
123
. In line with these in vivo 
findings, O'Hagan et al. recently showed in vitro that oxidative damage recruits 
complexes containing DNMTs, a histone deacetylase (sirtuin 1, SIRT1), and histone 
methyltransferase (enhancer of zeste homolog 2, EZH2) to damaged chromatin, and 
induces DNA methylation
124
. They also showed that, in Apc
Min
 mice infected with an 
inflammation-inducing bacterium, Dnmt1 and Ezh2 are recruited to promoter CpG 
islands of untranscribed or minimally transcribed genes. Promoter CpG islands with 




Taken together, we can hypothesize a model for aberrant DNA methylation 
induction in vivo (Figure 5). Inflammatory signals mainly from macrophages, such as 
IL-1β, TNF-α, and IL-6, and oxidative stress, possibly produced by NO synthase, are 
likely to recruit a complex with DNMT1 and EZH2 to promoter CpG islands with 
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H3K27 me3 flag and without protection by RNA polymerase II. Since DNA 
methylation is harmful to a gene, aberrant DNA methylation is likely to be induced only 
rarely and at scattered CpG sites within a CpG island (seeds of methylation)
123
. Most 
"seeds of methylation" are erased during cell replication, but can lead to dense 
methylation of a CpG island at very low frequencies 
125, 126
. If such dense methylation is 
induced in a promoter CpG island of a tumor-suppressor gene, the tissue becomes 
predisposed to carcinogenesis, and forms an epigenetic field defect. 
In addition to aberrant DNA methylation of promoter CpG islands, cancer cells are 
characterized by global DNA hypomethylation as well as aberrant hypomethylation of 
oncogenes
99, 127
. Gastric mucosa infected by H. pylori displays global 
hypomethylation
128
. In this regard, it is interesting to note that AID has been recently 
shown to be involved in active DNA demethylation during fetal development
129
. 
Mechanistically, AID deaminates 5-methyl cytosine (5-mC) to yield T. This T would be 
subsequently removed by either of the T:G mismatch-specific glycosylases, thymidine 
DNA glycosylase or methyl-CpG binding domain protein 4 (MBD4). The resulting 
abasic site would then be replaced by an unmethylated C via base excision repair 
processes, resulting in DNA demethylation. Notably, AID participates in active 
demethylation by 5-mC hydroxylase, ten-eleven translocation 1 (TET1), and subsequent 
gene expression in the dentate gyrus of adult mouse brain
130
. Thus, whether AID is 
involved in DNA demethylation during cancer development is an interesting topic for 
future studies 
131
. The fact that AID targets the chromatin marked by H3K4 me3 histone 
modification
132
, in contrast to preferential DNA methylation at promoter CpG islands 
with H3K27 me3 histone modification
101, 102
, might suggest opposing mechanisms for 
induction of DNA methylation and demethylation. 
      
Inflammation and MicroRNA Modulation 
 
MicroRNAs (miRNAs) are short noncoding RNAs that regulate the expression of 
many target genes post-transcriptionally, and are thus involved in a variety of cellular 
functions. Recent studies have revealed that miRNAs have important roles in cancer 
development as either oncogenes or tumor suppressor genes by regulating various 
cancer-related proteins or mRNA expressions
133, 134
. Indeed, cancer cells are associated 
with dysregulation of many miRNA expressions, which occurs through a variety of 
mechanisms, such as genetic changes, epigenetic regulation, or altered expression of 
transcription factors
135
. On the other hand, miRNA expression is also altered in 
inflammatory conditions, and such alterations in miRNA expression appear to play roles 
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not only in controlling chronic inflammation, but also in promoting cancer 
development
136, 137
. Many of the changes in miRNA expressions observed in 
inflammatory tissues are derived from immune cells that may participate in 
hematopoietic tumorigenesis
138
. However, recent reports have shown that inflammation 
also induces changes in cancer-related miRNAs in epithelial cells, suggesting a direct 




miRNA expressions in epithelial cells can be altered during inflammation through 
various mechanisms such as NF-κB activation by toll-like receptors (TLRs) or 
cytokine stimulation and STAT3 phosphorylation by IL-6 or other cytokines
139-143
. 
Among those, several miRNAs are identified as tumor suppressor miRNAs. miR-7 
targets not only Egfr but also latrophilin (Lphn2), brain abundant, membrane attached 
signal protein 1 (Basp1) and musculoaponeurotic fibrosarcoma oncogene homolog 
(Mafg), and thus is considered to be a tumor suppressor miRNA
142
. In a mouse model of 
inflammation-associated cancer development, expression of miR-7 has been shown to 
be inhibited by activated macrophages in Helicobacter-infected gastritis mucosa, being 
involved in gastric cancer development, whereas it was increased in germ-free 
conditions
142
. Lethal-7 (Let-7), consisting of 12 members, targets the RAS family and 
c-MYC 
144, 145
, and genomic locations of let-7 family members are frequently deleted in 
colon cancers and other solid cancers
146
. NF-κB activation enhances Lin28B 
transcription that causes posttranscriptional inhibition of let7 family member expression, 
and let-7 directly inhibits IL-6 expression, a cytokine often produced in cancer cells. 
Thus, reduction of let-7 expression by NF-κB activation appears to play a role in a 
positive feedback loop for NF-κB activation through an increase of IL-6 in cancer cells 
147
. 
miR-155, a possible oncogenic miRNA, is involved in blood cell maturation, 
immune responses and autoimmune disorders, and high expression of miR-155 is 
associated with the development of myeloproliferative disorders
148
. Recent studies have 
revealed a direct link between elevation of miR-155 and tumor formation and 
development in gastric and colon cancers
148, 149
. miR-155 expression is induced by NF-
κ B, IFN-β and TLR stimulation150, and thus enhanced by H. pylori and 
lipopolysaccharadie (LPS) treatment
151
. Recently, Croce et al.
143
 reported that 
TNF-α/LPS stimulation enhances miR-155 expression in association with an increased 
mutation rate. They also showed that miR-155 targets mitosis inhibitor protein kinase 1 
(WEE1), which blocks cell-cycle progression, and therefore reasoned that reduction of 
WEE1 by miR-155 allowed cell division to continue even in the presence of DNA 
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damage, leading to enhanced mutation induction. In another study, they also 
demonstrated that miR-155 promotes gene mutations by down-regulating the core 
mismatch repair proteins, hMSH2, hMSH6 and hMLH1
152
. Of particular interest are the 
recent reports showing that miR-155 negatively regulates AID in B cells. Teng et al.
153
 
demonstrated that miR-155 is upregulated in B cells undergoing class-switch 
recombination, and regulates the germinal center reaction by modulating AID. 
Moreover, miR-155 has been suggested to inhibit MYC-IGH translocation by reducing 
AID mRNA and protein in B cells 
154
. Thus, although an inhibitory effect of miR-155 on 
AID has not been examined in non-B cells, miR-155 may also have a tumor suppressor 
function in epithelial cells by inhibiting AID production. 
A miRNA expression pattern distinct from normal colonic mucosa has been found 
in the colonic mucosa and colitic tumor of patients with IBD as well as mice with 
colonic inflammation, including upregulation of miR-21 and miR-3 
155
. miR-21 is one of 
the most highly expressed miRNAs in colonic tissues of patients with ulcerative 
colitis
155
, and its expression is enhanced by LPS and IL-6 through STAT3 activation, 
targeting key regulators of cell proliferation and apoptosis such as phosphatase and 
tensin homolog (PTEN) and programmed cell death 4 (PDCD4)
156
. Olaru et al.
157
 
recently demonstrated that in colitic cancer development miR-31 expression increases in 
a stepwise fashion from IBD to cancer, and that miR-31 directly targets regulating factor 
inhibiting hypoxia inducible factor 1 (FIH-1), decreasing its repressor activity for 
hypoxia-inducible factor 1 (HIF-1). 
It is now evident that miRNAs exert various functions in inflammation-associated 
cancer development. However, alterations of miRNA expression observed in 
inflammatory tissues occur in both immune cells and epithelial cells. Accordingly, it is 
important to dissect miRNA changes in the two cell types, as the patterns of the miRNA 
changes are different between immune cells and epithelial cells. Further elucidation of 
the changes of miRNA expression, particularly in epithelial cells, will facilitate our 
understanding of the role of tumor-related miRNAs in inflammation-associated cancer 
development.  
 
Application to Cancer Prevention, Diagnostics, and Therapeutics 
 
In order to prevent inflammation-associated cancer development, it is crucial to 
cure or control inflammation. Indeed, it has been repeatedly demonstrated that 
long-term therapy with anti-inflammatory drugs resulted in fewer appearances of 
tumors
158
. The best way to control chronic inflammation is, of course, to eliminate 
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causative infections. In other cases unrelated to infection such as IBD and PSC, one 
approach is to block the action of key regulators of inflammation. In this regard, NF-κ
B or STAT3, and their activators TNF-α or IL-6, respectively, may be good targets for 
suppressing the inflammatory response. However, since treatment usually needs to be 
continued for long periods to control chronic inflammation, agents without serious side 
effects with lower costs should be developed. For this purpose, many natural agents 
derived from vegetables, fruits, spices, and their components have been tested. Among 
them, curcumin, derived from yellow spice turmeric (Curcuma longa) has been used for 
centuries, and has been shown to suppress NF-κB- as well as STAT3-regulated 
inflammation
159
, and thus can be administered safely over the long-term
160
. Indeed, a 
recent study showed that curcumin reduced TNF- α  expression, prevented 
cancer-associated weight loss, and induced apoptosis of tumors in patients with 
colorectal cancer
161
. Resveratrol, a natural polyphenolic, non-flavonoid antioxidant 
found in grapes and other berries has been shown to have generalized inhibitory effects 
on inflammation-related molecules such as NF-κB, COX2 and tyrosine kinases162. 
Recently, Resveratrol was found to alter the expression of many tumor-related 
miRNAs
163
. Similar types of agents may have the potential to both prevent and treat 
cancers
164
.   
In contrast to controlling inflammatory mediators, blocking genetic modulation 
appears to be difficult. One might consider inhibiting AID. However, because AID plays 
a critical role in immunoglobulin maturation in B cells, specific targeting for AID in the 
epithelial cells without affecting AID in B cells is critical. Control of epigenetic 
modulation can be considered from two aspects: suppression of methylation induction 
and reversal of induced methylation. Since induction of methylation is not essential in 
adult somatic cells, control of this process is a promising approach to prevent chronic 
inflammation-associated cancers. On the other hand, reversal of aberrant DNA 
methylation is an attractive idea to repair an epigenetic field defect, but targeting only 
aberrant DNA methylation without affecting physiological DNA methylation is 
currently very difficult. 
H. pylori eradication ameliorates chronic inflammation, and reduces the risk for 
gastric cancer. However, it is apparent that eradication cannot completely resolve 
chronic inflammation, as some patients develop gastric cancer even after successful 
eradication
165
. Likewise, some patients with chronic hepatitis or liver cirrhosis due to 
HCV infection also develop HCC after obtaining sustained virological response 
(SVR)
166
. As such, when inflammation is not appropriately controlled or even when 
inflammation is resolved after long-standing inflammation, accurate prediction for the 
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risk of developing cancers in the inflammatory tissues becomes important. As was 
discussed, carcinogenesis is characterized by a stepwise accumulation of both genetic 
and epigenetic changes. Importantly, previous data suggested that the extent of those 
genetic and epigenetic modulations is paralleled with duration or severity of 
inflammation
15, 167
, and the degree of epigenetic field defect can be measured relatively 
easily and accurately. Thus, both qualitative and quantitative detection of these genetic 
and epigenetic changes in inflammatory tissues or tissues previously exposed to 
inflammation may provide a good risk marker for inflammation-associated cancer 
development. Indeed, epigenetic risk markers that can differentiate gastric mucosae of 
cancer patients from those of healthy individuals with odds ratios between 12.7-36.0 
have been isolated
168, 169




Many cancers in digestive organs develop in the background of chronic 
inflammation. During chronic inflammation, a variety of mediators for inflammation 
such as cytokines, growth factors, eicosanoids, ROS and NOS form complex networks 
for not only maintaining or reducing inflammation but also promoting cell growth, 
angiogenesis and inhibiting apoptosis. These events eventually merge into and result in 
both genetic and epigenetic changes of the cellular genome, leading to 
inflammation-associated cancer development. In particular, AID plays a crucial role in 
inducing not only mutations, but also chromosomal aberrations during inflammation. 
Moreover, signals from macrophages with resulting mislocalization of DNMTs appear 
to be involved in the induction of epigenetic alterations.                                                
Interestingly, epigenetic inactivation of MLH1 leads to accumulation of genetic 
alterations
170
. At the same time, recent studies have demonstrated that AID induces 
DNA demethylation through its deaminating activity on methylated cytosines
131
. Thus, 
genetic and epigenetic events are mutually related and work in concert in the 
development of inflammation-associated cancers. 
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Table 1. Inflammation-associated cancers in digestive organs 
___________________________________________________________ 
Inflammation-                Underling inflammation 
associated cancer 
__________________________________________________________ 
Barrett’s cancer Reflux esophagitis 
Gastric cancer H. pylori-induced chronic gastritis 
Colitic cancer Inflammatory bowel disease 
 Celiac disease 
HCC HCV and HBV chronic hepatitis 
 Primary biliary cirrhosis 
Cholangiocarcinoma Primary sclerosing cholangitis 
Pancreatic cancer Chronic pancreatitis 
 Hereditary pancreatitis 
 
Lymphoma H. pylori-induced MALT lymphoma 
 HCV-associated lymphoma 
 Celiac disease-associated lymphoma 
___________________________________________________________ 
HCC; hepatocellular carcinoma 
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Figure Legends 
 
Figure 1. Molecular link between inflammation, genetic and epigenetic alterations, and 
carcinogenesis. Inflammation contributes to ROS production and transcriptional 
upregulation of the DNA mutator enzyme, AID. These two factors were capable of 
inducing somatic mutations and chromosomal aberrations in tumor-related genes. On 
the other hand, inflammation results in mislocalization of DNMTs, inducing aberrant 
DNA methylation.  The resulting genetic and epigenetic changes, including the 
activation of oncogenes, inactivation of tumor-suppressor genes, and dysregulation of 
DNA repair genes, could further enhance genetic instability, finally leading to 
carcinogenesis. 
 
Figure 2. Mechanism of mutation induction by AID activity. AID deaminates cytosine 
(C), resulting in the generation of a uracil (U) and therefore can transform a DNA C:G 
pair into a U:G mismatch. The AID-generated U:G mismatch can be recognized by 
UNG or MSH2/MSH6 heterodimer and repaired correctly (a). If DNA replication starts 
before recognition by the repair system, a U:G mismatch gives rise to C/G to T/A 
transition (b). Alternatively, generation of an abasic site by UNG (c) or recognition of 
the U:G mismatch by the MSH2/MSH6 heterodimer (d) induces any mutations in the 
AID-generated U:G mismatch or at a nearby A:T site, respectively, in an error-prone 
manner (indicated as M). 
 
Figure 3. AID exerts both favorable and unfavorable effects. AID is a molecule that is 
indispensable for the diversification of immunoglobulin genes by inducing both somatic 
hypermutation and class-switch recombination in activated B lymphocytes. The 
genotoxic activity of AID, however, can be aimed to trigger the genetic alterations at 
both the nucleotide and chromosomal levels in not only B lymphocytes but also 
epithelial cells in the inflammatory conditions. 
 
Figure 4. The degree of epigenetic field defects can be assessed using methylation 
levels of appropriate marker CpG islands, mostly passengers. Receiver-operating 
characteristic (ROC) curves were drawn to distinguish gastric mucosae of gastric cancer 
patients and those of healthy individuals with past infections by H. pylori. The ROC 
curves of newly isolated methylation risk markers, CpG islands #3 and #7, had a much 
larger area under the curve (AUC) values than those of two previously isolated markers, 
filamin Cγ (FLNc) and thrombomodulin (THBD), reaching 0.78–0.84. Modified from 





Figure 5. Current model of aberrant DNA methylation induction by chronic 
inflammation. Cytokines, such as IL-1β  and TNF-α  from macrophages, and 
oxidative stress, such as NO, are likely to recruit EZH2 and DNMT1 to a promoter CpG 
island of a gene with a flag of H3K27 me3 and without protection by RNA polymerase 
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